Genmab A/S (GMAB)
Healthcare • Biotechnology
StockNasdaqGSDenmarkUS3723032062
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Genmab A/S, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 12 Nov 2026 21:11. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 16 Feb 2027 16:00 | 0.40 | — | — | Upcoming |
| 05 Nov 2026 11:00 | 0.35 | 0.55 | +55.3% | Beat |
| 06 Aug 2026 11:00 | 0.33 | 0.49 | +47.5% | Beat |
| 07 May 2026 11:00 | 0.19 | 0.13 | -29.7% | Miss |
| 17 Feb 2026 11:00 | 0.37 | 0.21 | -44.6% | Miss |
| 06 Nov 2025 11:00 | 0.45 | 0.65 | +42.3% | Beat |
| 07 Aug 2025 11:00 | 0.34 | 0.54 | +61.4% | Beat |
| 08 May 2025 11:00 | 0.23 | 0.31 | +34.1% | Beat |
| 12 Feb 2025 11:00 | 0.28 | 0.84 | +203.1% | Beat |
| 06 Nov 2024 11:00 | 0.33 | 0.29 | -14.7% | Miss |
| 08 Aug 2024 11:00 | 0.32 | 0.32 | -0.9% | In line |
| 02 May 2024 11:00 | 0.14 | 0.29 | +103.0% | Beat |
| 14 Feb 2024 11:00 | 0.30 | 0.14 | -52.9% | Miss |
| 07 Nov 2023 11:00 | 0.31 | 0.46 | +47.7% | Beat |
| 03 Aug 2023 11:00 | 0.29 | 0.30 | +4.2% | Beat |
| 10 May 2023 11:00 | 0.15 | 0.05 | -67.1% | Miss |
| 22 Feb 2023 11:00 | 0.33 | 0.13 | -61.7% | Miss |
| 09 Nov 2022 11:00 | 0.20 | 0.53 | +161.2% | Beat |
| 10 Aug 2022 11:00 | 0.20 | 0.40 | +100.3% | Beat |
| 11 May 2022 11:00 | 0.19 | 0.10 | -47.6% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 3.7B | +19.2% | 963M | 25.9% | 1.54 | -9.2% | 1.1B |
| 2024 | 3.1B | +30.6% | 1.1B | 36.3% | 1.69 | +76.7% | 1.1B |
| 2023 | 2.4B | +14.5% | 631M | 26.4% | 0.96 | -20.4% | 1B |
| 2022 | 2.1B | — | 784.7M | 37.6% | 1.20 | — | 517.4M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 52.22 | 53.03 | 51.54 | 51.74 | -3.95% | 5,605,887 | |
| 11 Nov 2026 | 52.89 | 54.09 | 52.32 | 53.87 | -0.37% | 3,917,300 | |
| 10 Nov 2026 | 54.87 | 55.23 | 53.15 | 54.07 | -3.10% | 3,093,300 | |
| 09 Nov 2026 | 54.36 | 55.91 | 53.31 | 55.80 | +4.05% | 5,136,900 | |
| 06 Nov 2026 | 52.36 | 54.15 | 51.22 | 53.63 | +1.69% | 7,827,800 | |
| 05 Nov 2026 | 55.07 | 55.27 | 52.62 | 52.74 | -4.32% | 4,398,900 | |
| 04 Nov 2026 | 56.01 | 56.20 | 53.76 | 55.12 | -0.72% | 4,298,800 | |
| 03 Nov 2026 | 55.46 | 56.50 | 55.10 | 55.52 | +1.09% | 3,060,800 | |
| 02 Nov 2026 | 56.21 | 56.84 | 54.65 | 54.92 | -3.75% | 4,424,100 | |
| 30 Oct 2026 | 57.40 | 59.02 | 56.53 | 57.06 | +1.01% | 8,648,200 | |
| 1,249 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (opens in a new tab) 10 Nov 2026 22:57
- Capital Increase in Genmab as a Result of Employee Warrant Exercise (opens in a new tab) 10 Nov 2026 20:32
- Is Genmab (CPSE:GMAB) Fully Priced After Holding 2026 Guidance Steady? (opens in a new tab) Simply Wall St. · 08 Nov 2026 13:13
- What Is Genmab (CPSE:GMAB) Signaling With New Cancer Trial Data? (opens in a new tab) Simply Wall St. · 08 Nov 2026 12:13
- Genmab (GMAB) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 06 Nov 2026 16:16
- Moody’s lifts Genmab outlook to positive on pipeline progress, debt reduction (opens in a new tab) Investing.com · 06 Nov 2026 16:02
- Genmab AS (GMAB) (Q3 2026) Earnings Call Highlights: Revenue Jumps 22% as Epkinly and Pipeline ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 07:15
- What Genmab A/S (GMAB) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 05 Nov 2026 20:14
- Genmab nine-month revenue rises 22% as late-stage pipeline delivers (opens in a new tab) 05 Nov 2026 18:07
- Genmab shares fall 3% after Q3 revenue slightly misses expectations (opens in a new tab) Investing.com · 05 Nov 2026 18:07
- Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 05 Nov 2026 17:54
- Genmab Q3 EPS $5.51 Beats $3.59 Estimate, Sales $1.187B Miss $1.194B Estimate (opens in a new tab) Benzinga · 05 Nov 2026 17:01
- Genmab Affirms FY2026 Sales Guidance of $4.325B-$4.525B vs $4.472B Est (opens in a new tab) Benzinga · 05 Nov 2026 16:53
- Genmab Announces Financial Results for the Nine Months of 2026 (opens in a new tab) 05 Nov 2026 16:02
- Genmab Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 05 Nov 2026 14:27
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 53.87 USD
- Market cap
- 32.4B
- Exchange
- NasdaqGS
- Country
- Denmark
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow GMAB and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.